Treatment for severe neutropenia in certain cancer patients approved by FDA
Rebecca Aris
pharmaphorum
The FDA today approved Sicor Biotech’s tbo-filgrastim to reduce the time patients experience severe neutropenia in certain patients receiving cancer chemotherapy.
Neutropenia is a decrease in infection-fighting white blood cells called neutrophils.
Tbo-filgrastim is intended for use in adults who have cancers other than blood or bone marrow cancers and are taking chemotherapy drugs that cause severe neutropenia. It acts by stimulating the bone marrow to increase production of neutrophils.
“Supportive care products, such as tbo-filgrastim, reduce or allow for more rapid recovery from side effects of cancer treatments,”
Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.
 ,
 ,
Reference links:
 ,
